by Researchers from MIT and Dana-Farber Cancer Institute have uncovered a key strategy employed by early-stage cancer cells to escape detection by the immune system, allowing them to progress into more advanced tumors. The study focused on colon cancer development and revealed that cells activating a gene called SOX17 become invisible to immune surveillance in the early stages of the disease.
The activation of the SOX17 gene program plays a crucial role in shielding precancerous cells from the immune system during the initial phases of colorectal cancer. Inhibiting this program could potentially offer a new approach to treating early-stage cancers before they advance into larger tumors, according to Omer Yilmaz, MIT associate professor of biology and senior author of the study.
The research, published in Nature, was led by MIT research scientist Norihiro Goto, with contributions from Judith Agudo of Dana-Farber Cancer Institute and Harvard Medical School. The study utilized a model system to investigate how precancerous growths evade immune detection, focusing on the expression of SOX17 in colon tumors.
In their experiments involving mini colon tumors implanted in mice, the researchers observed a significant increase in SOX17 expression in response to mutated cancer-linked genes. The activation of SOX17 in cancer cells created an environment that suppressed immune responses by inhibiting interferon gamma receptor synthesis, a critical immune signaling molecule for targeting cancer cells.
SOX17 essentially turns off interferon gamma signaling in colorectal cancer cells, preventing them from displaying cancerous antigens and evading T cell-mediated immune responses. By disrupting SOX17 function in colon tumor organoids, the researchers demonstrated enhanced immune recognition and targeting of the tumor cells, suggesting a potential therapeutic strategy for early-stage colon cancer intervention.
Furthermore, the analysis of gene expression data from colon cancer patients revealed a pattern of SOX17 overexpression in early-stage tumors, which decreased as the cancer progressed to more invasive and metastatic stages. The researchers speculated that as cancer cells activate other mechanisms to create an immunosuppressive environment, the importance of SOX17 diminishes in later stages of colorectal cancer.
Despite the challenges associated with targeting transcription factors like SOX17 with conventional drugs, the researchers plan to explore alternative strategies by identifying protein interactions associated with SOX17. Additionally, further investigation into the triggers of SOX17 activation in precancerous cells may provide valuable insights for developing novel therapeutic interventions for early-stage cancers.
The findings from this study offer a promising avenue for understanding how early-stage cancer cells evade immune surveillance and suggest potential targets for future therapeutic interventions in the fight against colorectal cancer.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
